JP2023539625A5 - - Google Patents
Info
- Publication number
- JP2023539625A5 JP2023539625A5 JP2023513704A JP2023513704A JP2023539625A5 JP 2023539625 A5 JP2023539625 A5 JP 2023539625A5 JP 2023513704 A JP2023513704 A JP 2023513704A JP 2023513704 A JP2023513704 A JP 2023513704A JP 2023539625 A5 JP2023539625 A5 JP 2023539625A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- free base
- composition
- combination
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070376P | 2020-08-26 | 2020-08-26 | |
| US63/070,376 | 2020-08-26 | ||
| PCT/US2021/047826 WO2022047083A1 (en) | 2020-08-26 | 2021-08-26 | Cancer treatment with tlr agonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539625A JP2023539625A (ja) | 2023-09-15 |
| JP2023539625A5 true JP2023539625A5 (https=) | 2024-08-30 |
Family
ID=80355767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513704A Pending JP2023539625A (ja) | 2020-08-26 | 2021-08-26 | Ｔｌｒアゴニストによるがんの処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230346775A1 (https=) |
| EP (1) | EP4203962A4 (https=) |
| JP (1) | JP2023539625A (https=) |
| KR (1) | KR20230057409A (https=) |
| CN (1) | CN116056710A (https=) |
| AU (1) | AU2021332350A1 (https=) |
| CA (1) | CA3192776A1 (https=) |
| WO (1) | WO2022047083A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3092256T3 (da) | 2014-01-10 | 2022-06-20 | Birdie Biopharmaceuticals Inc | Forbindelser og sammensætninger til immunterapi |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CA3067268A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Crystalline resiquimod monosulfate anhydrate and its preparation and uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3092256T3 (da) * | 2014-01-10 | 2022-06-20 | Birdie Biopharmaceuticals Inc | Forbindelser og sammensætninger til immunterapi |
| CN121243402A (zh) * | 2014-07-09 | 2026-01-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1组合 |
| CA3067268A1 (en) * | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Crystalline resiquimod monosulfate anhydrate and its preparation and uses |
-
2021
- 2021-08-26 AU AU2021332350A patent/AU2021332350A1/en active Pending
- 2021-08-26 US US18/023,306 patent/US20230346775A1/en active Pending
- 2021-08-26 JP JP2023513704A patent/JP2023539625A/ja active Pending
- 2021-08-26 EP EP21862771.9A patent/EP4203962A4/en active Pending
- 2021-08-26 KR KR1020237009853A patent/KR20230057409A/ko active Pending
- 2021-08-26 CA CA3192776A patent/CA3192776A1/en active Pending
- 2021-08-26 CN CN202180053175.7A patent/CN116056710A/zh active Pending
- 2021-08-26 WO PCT/US2021/047826 patent/WO2022047083A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539625A5 (https=) | ||
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| IL270253B1 (en) | Stable formulations of PROGRAMMED DEATH RECEPTOR 1 (PD–1) antibodies and methods of using them | |
| JP2024156992A (ja) | 関節リウマチの治療 | |
| KR102314003B1 (ko) | 종양성 질병들에 대한 치료 | |
| JP2019530752A (ja) | がんを治療するための薬物の調製における、抗ｐｄ‐１抗体とｖｅｇｆｒ阻害剤とを組み合わせた使用 | |
| JP2020500152A5 (https=) | ||
| JP2018515493A5 (https=) | ||
| US20220257630A1 (en) | Administration of sting agonist and checkpoint inhibitors | |
| JP2022531408A5 (https=) | ||
| WO2020187152A1 (zh) | 治疗小细胞肺癌的联用药物组合物 | |
| TW202033188A (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| CN114746117A (zh) | 抗dll3药剂的给药方案 | |
| JP2023505217A (ja) | 皮下投与のための抗ｃｄ３８抗体の製剤 | |
| JP2019519584A5 (https=) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| CN105813637A (zh) | 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂 | |
| JP2022513029A5 (https=) | ||
| ES2935265T3 (es) | Método para tratar acontecimientos adversos inducidos por inhibidores de punto de control | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| JP2017515843A (ja) | 抗ｅｇｆｒ治療薬の投与量および投与 | |
| WO2022107027A1 (en) | Administration of sting agonist, checkpoint inhibitors, and radiation | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| US20240207199A1 (en) | Fluorocarbon compositions and methods for enhancing immunotherapy | |
| CN118871128A (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 |